GlassScriptPhysician profile
Arin H Newman
NPI 1447256540
$716,064.62
in general payments reported to CMS, 2019-2025
45 companies · $195K in 2025
The $195K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $33K · 2021: $128K · 2022: $57K · 2023: $60K · 2024: $140K · 2025: $195K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $342K · Travel and Lodging: $35K · Food and Beverage: $15K · Consulting Fee: $3,463 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $342,408.75 |
| Travel and Lodging | $34,582.08 |
| Food and Beverage | $14,998.38 |
| Consulting Fee | $3,462.50 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $200,890.21 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $177,484.68 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99,958.14 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $93,121.69 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $84,286.43 | 2024-2025 | Voquezna |
| Allergan, INC. | $51,219.67 | 2019-2020 | |
| Boston Scientific Corporation | $1,433.25 | 2019-2024 | Exalt Model D, Resolution 360 Clip, Axios |
| Janssen Biotech, INC. | $1,138.33 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $803.84 | 2019-2023 | Ocaliva |
| Janssen Scientific Affairs, LLC | $659.33 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $627.90 | 2019-2025 | Eohilia, Entyvio |
| Ironwood Pharmaceuticals, INC | $608.38 | 2019-2021 | |
| Novo Nordisk INC | $418.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $413.82 | 2022-2024 | |
| Madrigal Pharmaceuticals | $347.72 | 2024-2025 | Rezdiffra |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $273.12 | 2021-2023 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $243.80 | 2022-2023 | Zeposia |
| Pfizer INC. | $209.49 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $188.91 | 2021 | |
| Idorsia Pharmaceuticals US INC | $180.79 | 2023 | Quviviq |
| Medtronic, INC. | $170.65 | 2022 | |
| Abbott Laboratories | $117.03 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Qol Medical, LLC | $110.68 | 2019-2021 | |
| Lilly USA, LLC | $107.06 | 2021-2024 | Mounjaro, Zepbound, Omvoh |
| Exact Sciences Corporation | $97.40 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $95.00 | 2022 | |
| Viiv Healthcare Company | $92.68 | 2023-2025 | Apretude |
| Ardelyx, INC. | $91.66 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $91.65 | 2019-2024 | Farxiga |
| Celltrion USA INC. | $87.20 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $64.61 | 2024 | Iqirvo |
| Braintree Laboratories, INC. | $51.45 | 2020-2025 | Sutab |
| Otsuka America Pharmaceutical, INC. | $46.25 | 2023 | Rexulti |
| Genzyme Corporation | $44.65 | 2024 | |
| Merck Sharp & Dohme LLC | $38.62 | 2024 | Dificid |
| Shire North American Group INC | $38.57 | 2019 | |
| Redhill Biopharma INC. | $37.00 | 2020-2022 | |
| Ibsa Pharma INC. | $35.51 | 2024-2025 | Tirosint, Licart, Flector |
| Regeneron Healthcare Solutions, INC. | $26.19 | 2023 | Dupixent |
| Eisai INC. | $22.77 | 2024 | |
| Glaxosmithkline, LLC. | $19.96 | 2023 | Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $17.81 | 2019 | |
| Currax Pharmaceuticals LLC | $17.45 | 2021 | |
| Saluda Medical Americas, INC. | $17.23 | 2024 | Evoke |
| Alvogen INC | $17.19 | 2023 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arin Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.